JP2018535650A5 - - Google Patents

Download PDF

Info

Publication number
JP2018535650A5
JP2018535650A5 JP2018514962A JP2018514962A JP2018535650A5 JP 2018535650 A5 JP2018535650 A5 JP 2018535650A5 JP 2018514962 A JP2018514962 A JP 2018514962A JP 2018514962 A JP2018514962 A JP 2018514962A JP 2018535650 A5 JP2018535650 A5 JP 2018535650A5
Authority
JP
Japan
Prior art keywords
antibody
antigen
binding fragment
nucleic acid
hepatitis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018514962A
Other languages
English (en)
Japanese (ja)
Other versions
JP6869968B2 (ja
JP2018535650A (ja
Filing date
Publication date
Priority claimed from PCT/EP2015/001970 external-priority patent/WO2017059878A1/en
Application filed filed Critical
Publication of JP2018535650A publication Critical patent/JP2018535650A/ja
Publication of JP2018535650A5 publication Critical patent/JP2018535650A5/ja
Priority to JP2021068062A priority Critical patent/JP7171809B2/ja
Application granted granted Critical
Publication of JP6869968B2 publication Critical patent/JP6869968B2/ja
Priority to JP2022175909A priority patent/JP2023011809A/ja
Priority to JP2024074160A priority patent/JP2024097078A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018514962A 2015-10-07 2016-10-07 B型肝炎ウイルスを強力に中和する抗体及びその使用 Active JP6869968B2 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2021068062A JP7171809B2 (ja) 2015-10-07 2021-04-14 B型肝炎ウイルスを強力に中和する抗体及びその使用
JP2022175909A JP2023011809A (ja) 2015-10-07 2022-11-02 B型肝炎ウイルスを強力に中和する抗体及びその使用
JP2024074160A JP2024097078A (ja) 2015-10-07 2024-05-01 B型肝炎ウイルスを強力に中和する抗体及びその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/EP2015/001970 WO2017059878A1 (en) 2015-10-07 2015-10-07 Antibodies that potently neutralize hepatitis b virus and uses thereof
EPPCT/EP2015/001970 2015-10-07
PCT/EP2016/074114 WO2017060504A1 (en) 2015-10-07 2016-10-07 Antibodies that potently neutralize hepatitis b virus and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021068062A Division JP7171809B2 (ja) 2015-10-07 2021-04-14 B型肝炎ウイルスを強力に中和する抗体及びその使用

Publications (3)

Publication Number Publication Date
JP2018535650A JP2018535650A (ja) 2018-12-06
JP2018535650A5 true JP2018535650A5 (enExample) 2019-10-31
JP6869968B2 JP6869968B2 (ja) 2021-05-12

Family

ID=54330711

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2018514962A Active JP6869968B2 (ja) 2015-10-07 2016-10-07 B型肝炎ウイルスを強力に中和する抗体及びその使用
JP2021068062A Active JP7171809B2 (ja) 2015-10-07 2021-04-14 B型肝炎ウイルスを強力に中和する抗体及びその使用
JP2022175909A Withdrawn JP2023011809A (ja) 2015-10-07 2022-11-02 B型肝炎ウイルスを強力に中和する抗体及びその使用
JP2024074160A Pending JP2024097078A (ja) 2015-10-07 2024-05-01 B型肝炎ウイルスを強力に中和する抗体及びその使用

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2021068062A Active JP7171809B2 (ja) 2015-10-07 2021-04-14 B型肝炎ウイルスを強力に中和する抗体及びその使用
JP2022175909A Withdrawn JP2023011809A (ja) 2015-10-07 2022-11-02 B型肝炎ウイルスを強力に中和する抗体及びその使用
JP2024074160A Pending JP2024097078A (ja) 2015-10-07 2024-05-01 B型肝炎ウイルスを強力に中和する抗体及びその使用

Country Status (24)

Country Link
US (3) US10683344B2 (enExample)
EP (2) EP3359564B1 (enExample)
JP (4) JP6869968B2 (enExample)
KR (1) KR102725168B1 (enExample)
CN (3) CN114539392B (enExample)
AU (1) AU2016334735B2 (enExample)
BR (1) BR112018002406A2 (enExample)
CA (1) CA2993745A1 (enExample)
CY (1) CY1123462T1 (enExample)
DK (1) DK3359564T3 (enExample)
EA (1) EA038301B1 (enExample)
ES (1) ES2813927T3 (enExample)
HR (1) HRP20201345T1 (enExample)
HU (1) HUE050231T2 (enExample)
IL (1) IL258326B (enExample)
LT (1) LT3359564T (enExample)
MX (1) MX2018004127A (enExample)
MY (1) MY187161A (enExample)
PH (1) PH12018500199A1 (enExample)
PL (1) PL3359564T3 (enExample)
PT (1) PT3359564T (enExample)
SI (1) SI3359564T1 (enExample)
WO (2) WO2017059878A1 (enExample)
ZA (1) ZA201800710B (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017059878A1 (en) * 2015-10-07 2017-04-13 Humabs Biomed Sa Antibodies that potently neutralize hepatitis b virus and uses thereof
CN112513063A (zh) * 2018-05-10 2021-03-16 克莱尔博治疗有限公司 用于治疗乙型肝炎感染的方法和组合物
CN112770772A (zh) * 2018-05-16 2021-05-07 长庚医疗财团法人林口长庚纪念医院 新型富亮氨酸重复神经元蛋白1(lrrn1)抗体和其用途
CN112165974B (zh) 2018-05-31 2024-11-08 诺华股份有限公司 乙型肝炎抗体
SG11202105276TA (en) 2018-12-03 2021-06-29 Univ Texas Oligo-benzamide analogs and their use in cancer treatment
WO2020132091A2 (en) * 2018-12-19 2020-06-25 Humabs Biomed Sa Antibodies that neutralize hepatitis b virus and uses thereof
DK4285929T3 (da) * 2018-12-20 2025-12-22 Humabs Biomed Sa Kombinationsterapi mod hbv
KR102084912B1 (ko) * 2019-01-17 2020-03-05 주식회사 녹십자 B형 간염 바이러스 표면 항원의 입체 에피토프 및 이에 특이적으로 결합하는 항체
KR20220035483A (ko) 2019-07-20 2022-03-22 화후이 헬스 리미티드 항-pre-s1 hbv 항체를 이용한 hbv 감염 치료 방법
WO2021042000A1 (en) 2019-08-29 2021-03-04 Vir Biotechnology, Inc. Antibody compositions and methods for treating hepatitis b virus infection
CN113717283B (zh) * 2020-05-25 2023-05-26 厦门万泰凯瑞生物技术有限公司 一种抗乙型肝炎病毒e抗原的单克隆抗体及其应用
JP7579007B2 (ja) * 2020-06-02 2024-11-07 株式会社Rcmg Hbvの抗rnaウイルス粒子抗体
EP4161644A2 (en) * 2020-06-08 2023-04-12 F. Hoffmann-La Roche AG Anti-hbv antibodies and methods of use
US20210403908A1 (en) * 2020-06-22 2021-12-30 Janssen Pharmaceuticals, Inc. Compositions and methods for treatment of hepatitis d virus infection
CN116390943A (zh) 2020-06-24 2023-07-04 维尔生物科技有限公司 工程化乙型肝炎病毒中和抗体和其用途
TW202406932A (zh) 2020-10-22 2024-02-16 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
US20240092872A1 (en) 2021-01-26 2024-03-21 Vir Biotechnology, Inc. Compositions and methods for treating hepatitis b virus infection
CN113234144B (zh) * 2021-05-26 2022-02-25 武汉工程大学 一种人源性抗乙肝表面抗原的单链抗体、制剂、编码基因、载体质粒及宿主细胞
WO2023287352A2 (en) * 2021-07-15 2023-01-19 National University Of Singapore Anti-hbv antibodies and uses thereof
CN113777312B (zh) * 2021-09-03 2024-02-02 普十生物科技(北京)有限公司 乙肝抗体片段的制备方法、乙肝抗体片段、试剂盒及应用
US20240391979A1 (en) * 2021-09-13 2024-11-28 Achelois Biopharma, Inc. Hepatitis b virus antivirus (hbv-antivirus) compositions and methods of use
AU2022417396A1 (en) * 2021-12-21 2024-06-20 Hbvtech, Llc. Methods for eliminating hepatitis b virus cccdna and rcdna and the hepatitis b drugs used in the methods thereof
TW202411246A (zh) 2022-05-23 2024-03-16 美商維爾生物科技股份有限公司 經工程化之b型肝炎病毒中和抗體及其用途
CN116162153B (zh) * 2022-09-01 2024-09-10 复旦大学附属中山医院 一种乙肝病毒表面抗原的单克隆抗体及其应用
CN118725092B (zh) * 2023-03-28 2025-08-12 东莞市朋志生物科技有限公司 抗HBs-Ag抗体、检测HBs-Ag的试剂和试剂盒
IL324645A (en) * 2023-05-31 2026-01-01 Bluejay Therapeutics Inc Anti-HBsAg antibody for the treatment of chronic hepatitis D
CN119143869A (zh) * 2023-06-16 2024-12-17 复旦大学 乙肝病毒表面抗体及其应用

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3766162A (en) 1971-08-24 1973-10-16 Hoffmann La Roche Barbituric acid antigens and antibodies specific therefor
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4233402A (en) 1978-04-05 1980-11-11 Syva Company Reagents and method employing channeling
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
US4609546A (en) 1982-06-24 1986-09-02 Japan Chemical Research Co., Ltd. Long-acting composition
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4831175A (en) 1986-09-05 1989-05-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US5595721A (en) 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
JP2000514643A (ja) 1996-04-18 2000-11-07 アボツト・ラボラトリーズ B型肝炎表面抗原のa―決定基の抗原エピトープ及びその利用法
GB9608626D0 (en) * 1996-04-25 1996-07-03 Univ College Of London Hepatitis b monoclonal antibodies
WO1998029442A1 (en) * 1996-12-30 1998-07-09 Innogenetics N.V. ANNEXIN V-BINDING POLYPEPTIDES DERIVED FROM HBsAg AND THEIR USES
MY133346A (en) 1999-03-01 2007-11-30 Biogen Inc Kit for radiolabeling ligands with yttrium-90
US20020102208A1 (en) 1999-03-01 2002-08-01 Paul Chinn Radiolabeling kit and binding assay
EP1597280B2 (en) 2003-02-26 2016-08-24 Institute for Research in Biomedicine Monoclonal antibody production by ebv transformation of b cells
US20050163782A1 (en) 2003-06-27 2005-07-28 Biogen Idec Ma Inc. Modified binding molecules comprising connecting peptides
EP1848740A1 (en) * 2005-01-14 2007-10-31 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, the Department of Health and Human Services, Monoclonal antibodies that bind or neutralize hepatitis b virus
KR20100021601A (ko) 2007-05-14 2010-02-25 바이오겐 아이덱 엠에이 인코포레이티드 단일-쇄 Fc(ScFc) 부분, 이를 포함하는 결합 폴리펩타이드, 및 이에 관련된 방법
KR20090056537A (ko) * 2007-11-30 2009-06-03 주식회사 녹십자 B형 간염 바이러스 중화능을 갖는 항체를 유효성분으로포함하는 b형 간염 바이러스 감염의 예방 또는 치료용조성물
EP2848630A1 (en) 2008-10-22 2015-03-18 Institute for Research in Biomedicine Methods for producing antibodies from plasma cells
NZ705730A (en) * 2012-08-30 2016-06-24 Replicor Inc Methods for the treatment of hepatitis b and hepatitis d infections
CN104955837A (zh) * 2012-11-12 2015-09-30 海德堡吕布莱希特-卡尔斯大学 Hbv和/或hdv易感细胞、细胞系和非人动物的开发
CA2936877C (en) * 2014-01-16 2023-03-28 Mario Umberto Francesco MONDELLI Neutralizing human monoclonal antibodies against hepatitis b virus surface antigen
WO2017059878A1 (en) 2015-10-07 2017-04-13 Humabs Biomed Sa Antibodies that potently neutralize hepatitis b virus and uses thereof

Similar Documents

Publication Publication Date Title
JP2018535650A5 (enExample)
HRP20201345T1 (hr) Protutijela koja snažno neutraliziraju virus hepatitisa b i njihova upotreba
FI3484915T3 (fi) Uusia zikavirusepitooppeihin spesifisesti sitoutuvia vasta-aineita ja niiden käyttöjä
JP2022031635A5 (enExample)
JP2010516229A5 (enExample)
JP2011528902A5 (enExample)
JP2018521638A5 (enExample)
JP2012504955A5 (enExample)
RU2011105062A (ru) Нейтрализующие антитела против вируса гриппа а и их использование
RU2009129403A (ru) Антитела, нейтрализующие цитомегаловирус человека, и их применение
JP2019536806A5 (enExample)
JP2015534982A5 (enExample)
JP2018536393A5 (enExample)
JP2019504032A5 (enExample)
JP2015522252A5 (enExample)
JP2023071956A5 (enExample)
JP2015503909A5 (enExample)
RU2016129274A (ru) Канинизированные мышиные антитела к человеческому pd-1
JP2015514110A5 (enExample)
JP2018522540A5 (enExample)
CN106795219A (zh) 抗il‑17抗体及其生产和使用的方法
JP2014519334A5 (enExample)
JP2025032102A5 (enExample)
JP2016503413A5 (enExample)
JP2017537084A5 (enExample)